Welcome to NCI National Clinical Trials Network (NCTN) Biospecimen Banks

Formerly the Cooperative Group Banks (CGBs)

These banks represent the collective Biospecimen resources of the NCI’s NCTN.

The purpose of the NCTN Banks resource is to make available a supply of quality NCI Clinical Trials human biospecimens and to provide fair and open access to qualified investigators in the research community. NCTN Banks collect, store, and distribute specimens from patients treated in phase III and large phase II NCI-funded controlled randomized clinical trials. These well-annotated specimen collections are unique because they have associated patient clinical, treatment, and outcome data. In general, specimens are only available from trials that are closed (e.g., from trials that have completed analyses of the primary endpoints of the clinical trial) and the results published, although there may be rare exceptions.

The biospecimen collections developed from cancer clinical trials conducted by the National Cancer Institute’s (NCI’s) National Clinical Trials Network (NCTN) are highly annotated with carefully collected clinical data, including outcome data.

The NCTN Core Correlative Sciences Committee (NCTN-CCSC) is charged with scientific review and prioritization of proposals requesting use of banked, non-reserved biospecimens collected from NCTN clinical trials for use in correlative science studies. The NCTN-CCSC has oversight for ensuring optimal use of these irreplaceable clinical trial biospecimens.